Online and in-person exercise programs for cancer survivors in Canada

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The EXCEL program aims to provide tailored online and in-person exercise programs for individuals living with and beyond cancer across Canada. This initiative addresses the lack of cancer-specific exercise programs and trained specialists by offering community-based solutions to improve physical activity levels among cancer survivors. The program will streamline participant intake and simplify outcome assessments to enhance accessibility and engagement. By fostering stronger relationships with healthcare providers, the EXCEL program seeks to promote a patient-centered approach to cancer care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* have or had a diagnosis of cancer;
* be 18 years or older;
* be able to participate in low-intensity levels of activity, at minimum;
* be pretreatment, or receiving active cancer treatment (i.e., surgery, systemic therapy and radiation therapy), have received cancer treatment within the past 3 years, or if beyond 3 years since treatment completion, have a referral from their healthcare team indicating they have side effects from cancer treatment or the cancer itself, that could be improved or managed with exercise;
* be able to provide informed written consent in English or French

Exclusion Criteria:

* does not or did not have a cancer diagnosis
* is under the age of 18
* is unable to participate in mild exercise, at minimum
* is not pretreatment, or receiving active cancer treatment (i.e., surgery, systemic therapy and radiation therapy), has not received cancer treatment within the past 3 years, or if beyond 3 years since treatment completion, doesn't have side effects from cancer treatment or the cancer itself, that could be improved or managed with exercise
* unable to read/write in English
* for online programs, does not have internet or computer access

Where it's running

• University of Calgary
  Calgary, Alberta, Canada Recruiting
• University of British Columbia
  Vancouver, British Columbia, Canada Recruiting
• Nova Scotia Health Authority
  Halifax, Nova Scotia, Canada Recruiting
• University of Toronto
  Toronto, Ontario, Canada Recruiting
• Centre hospitalier de l'Université de Montréal
  Montreal, Quebec, Canada Recruiting

Study contacts

• Principal investigator: Nicole Culos-Reed, PhD — University of Calgary
• Study coordinator: Julianna Dreger, PhD
• Email: jdreger@ucalgary.ca
• Phone: (403) 210-8482

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Early‑phase KESONOTIDE™ treatment for solid tumors

  This trial tests an oral drug called KESONOTIDE™ (a vimentin inhibitor) to see if it is safe and tolerable in adults with advanced or metastatic solid tumors like prostate, breast, lung, ovarian cancer, or glioblastoma.

  Recruiting at 3 sites Phase 1/2 Filamon LTD · Kogarah, New South Wales and 2 other locations · NCT06926075

• Analysis of blood tumor markers for cancer diagnosis and treatment monitoring

  This study is testing whether a simple blood test can replace traditional tissue biopsies to help diagnose cancer and monitor how well treatments are working.

  Recruiting at 2 sites Institut du Cancer de Montpellier - Val d'Aurelle · Montpellier and 1 other locations · NCT04025541

• LTZ-232: a first-in-human test in advanced colorectal and other solid tumors

  A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.

  Recruiting Phase 1 LTZ Therapeutics, Inc. · Scottsdale, Arizona · NCT07878988

• ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer

  This study tests whether tracking ctDNA can guide neoadjuvant immunotherapy and surgical decisions for people with dMMR/MSI-H colon cancer, using PD-1 inhibitors first and adding CTLA-4 inhibitors if ctDNA remains detectable.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07841236

• Tafolecimab with chemoimmunotherapy as neoadjuvant treatment for locally advanced colon cancer

  This study tests whether adding tafolecimab to a chemoimmunotherapy regimen helps shrink locally advanced colon cancer before surgery in adults who have pMMR/MSS tumors.

  Recruiting Phase 2 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Chongqing, Chongqing Municipality · NCT07840677

• Neoadjuvant pembrolizumab and porustobart for resectable MSS colon cancer

  This trial tests whether giving pembrolizumab with porustobart before surgery can shrink MSS colon cancer and improve outcomes, comparing one versus two doses of porustobart.

  Recruiting at 3 sites Phase 2 Solstice Oncology, Inc. · Los Angeles, California and 29 other locations · NCT07808151

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.